Patient access to a medicine, post marketing authorisation, depends on increasing local and regional approval by drugs and therapeutics committees.

However, this only allows diagnosed patients to have access to the medicine.

Medialis has pioneered a specialised approach to:

  1. Patient characterisation
  2. Patient identification

This specialised approach will enable industry stakeholders, patient groups and prescribers, to expand the access to medicines to a population that would experience a benefit.

Medialis are specialists in Qualitative research methods.

This allows patients to be interviewed and characterised in a way traditional randomised control trials or observational studies are not designed to do.

Rare diseases often have long lead-times to diagnosis, and patient outcomes can be poorer the longer patients are left untreated.

Medialis has designed variations of its patient identification programme to service orphan diseases as well as primary care.